Anavex Life Sciences Product Blarcamesine for Alzheimer’s Disease Receives Promising News from the EMA

Anavex Life Sciences Promising News
From Anavex Life Sciences  (AVXL) we learned that The Committee for Medicinal Products for Human Use (CHMP) within the European Medicines agency (EMA) agreed that oral blarcamesine for Alzheimer’s disease is eligible for submission of application for a Union Marketing Authorization in the EU under the European Medicines Agency’s centralized procedure . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.